Relevant bibliographies by topics / Cancer nanotechnology

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cancer nanotechnology'

Author: Grafiati
Published: 4 June 2021
Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer nanotechnology.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cancer nanotechnology"

1

Jagdale, SwatiC, TejasP Shah, BhanudasS Kuchekar, AniruddhaR Chabukswar, and DhirajT Baviskar. "Cancer nanotechnology." Asian Journal of Pharmaceutics 3, no. 1 (2009): 4. http://dx.doi.org/10.4103/0973-8398.49166.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Grodzinski, Piotr, and Vladimir Torchilin. "Cancer nanotechnology." Advanced Drug Delivery Reviews 66 (February 2014): 1. http://dx.doi.org/10.1016/j.addr.2013.09.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Misra, Ranjita, Sarbari Acharya, and Sanjeeb K. Sahoo. "Cancer nanotechnology: application of nanotechnology in cancer therapy." Drug Discovery Today 15, no. 19-20 (October 2010): 842–50. http://dx.doi.org/10.1016/j.drudis.2010.08.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Bradley, David. "Nanotechnology fights cancer." Materials Today 13, no. 6 (June 2010): 10. http://dx.doi.org/10.1016/s1369-7021(10)70097-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Parida, Sushree, and Tushar Kanti Das. "Nanotechnology and Cancer." Apollo Medicine 5, no. 3 (September 2008): 250–52. http://dx.doi.org/10.1016/s0976-0016(11)60497-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Heath, James R., and Mark E. Davis. "Nanotechnology and Cancer." Annual Review of Medicine 59, no. 1 (February 2008): 251–65. http://dx.doi.org/10.1146/annurev.med.59.061506.185523.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bosetti, Rita, and Lode Vereeck. "On Cancer Nanotechnology." Key Engineering Materials 441 (June 2010): 307–32. http://dx.doi.org/10.4028/www.scientific.net/kem.441.307.

Full text
Abstract:
Although governments invest billions of dollars in cancer research, cancer remains one of the major causes of death worldwide (Liu et al., 2007). During the last decades, outstanding results have been attained in fundamental cancer biology but, unfortunately, they have not been translated in even distantly comparable progressions in the clinic. The main reason for this gap being the inability to administer therapeutic agents so that they can reach target cells without or with minimal side-effects (Ferrari, 2005). Today, scientists are faced with the recognition that very few molecules reach the desired locations and thus fail to selectively reach the target cells. Consequently, patients experience a very poor quality of life (Ferrari, 2004; Ferrari, 2005; Chan, 2006).
APA, Harvard, Vancouver, ISO, and other styles
8

Darmawikarta, Denise, and Alexander Pazionis. "Nanotechnology in cancer therapeutics." University of Western Ontario Medical Journal 82, no. 2 (July 30, 2014): 20–21. http://dx.doi.org/10.5206/uwomj.v82i2.4590.

Full text
Abstract:
The field of cancer therapeutics is rapidly evolving. Of particular interest is the potential for nanotechnology to overcome one of chemotherapy’s biggest barriers: targeted drug delivery. Owing to the sheer small size of nanoparticles, the opportunity arises for chemotherapy to be administered much more accurately to cancer cells while sparing healthy adjacent tissues. In this article, we review the various tools in nanotechnology that have emerged as candidate delivery systems for chemotherapeutic agents. We discuss the ways in which nanotechnology has been demonstrated to eradicate cancer cells and comment on both successes and current limitations.
APA, Harvard, Vancouver, ISO, and other styles
9

Acharya, Aditi. "Nanotechnology for Cancer Treatment." INROADS- An International Journal of Jaipur National University 5, no. 1s (2016): 30. http://dx.doi.org/10.5958/2277-4912.2016.00006.0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Aslan, Burcu, Bulent Ozpolat, Anil K. Sood, and Gabriel Lopez-Berestein. "Nanotechnology in cancer therapy." Journal of Drug Targeting 21, no. 10 (September 30, 2013): 904–13. http://dx.doi.org/10.3109/1061186x.2013.837469.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cancer nanotechnology"

1

Ullal, Adeeti (Adeeti Vedantham). "Micro and nanotechnology for cancer treatment." Thesis, Massachusetts Institute of Technology, 2013. http://hdl.handle.net/1721.1/83968.

Full text
Abstract:
Thesis (Ph. D. in Biomedical Engineering)--Harvard-MIT Program in Health Sciences and Technology, 2013.
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 92-101).
Cancer is responsible for over 7.6 million deaths worldwide; the majority of patients fail to respond to drugs or become resistant over time. In order to gain a better understanding of drug efficacy in patients, we developed three diagnostic technologies to address limitations in sample acquisition and improve the scale and sensitivity of current cancer diagnostic tools. In the first section, we describe a hybrid magnetic and size sorting microfluidic device that isolates rare circulating tumor cells from peripheral blood. The self-assembled magnetic sorter creates strong magnetic fields and effectively removes leukocytes tagged with magnetic nanoparticles. The size sorting region retains the remaining cells in single cell capture sites, while allowing small red blood cells to pass through 5pm gaps. The device achieves over 103 enrichment, up to 96% recovery of cancer cells and allows for on-chip molecular profiling. In the second section we use a magnetic nanoparticle decorated with small molecule drugs to assay target expression and drug binding in mock clinical samples of cancer cells spiked into whole blood. Specifically, we modify a PARP inhibitor (Olabarib) and conjugate it to a dextran coated iron oxide nanoparticle. We measure the presence of the drug nanosensor based on the change in T2 relaxation time using a miniaturized, handheld NMR sensor for point-of-care diagnosis. In the final section, we detail a photocleavable DNA barcoding method for understanding treatment response via multiplexed profiling of cancer cells. We validate our method with a 94 marker panel on different cell lines with varying treatments, showing high correlations to gold standard methods such as immunofluorescence and flow cytometry. Furthermore, we demonstrate single cell sensitivity, and identify a number of expected biomarkers in response to cell treatments. Finally, we demonstrate the potential of our method to help in clinical monitoring of patients by examining intra- and inter-patient heterogeneity, and by correlating pre and post-treatment tumor profiles to patient response. Together, we show how these technologies can help overcome clinical limitations and expedite advancements in cancer treatment.
by Adeeti Ullal
Ph.D.in Biomedical Engineering
APA, Harvard, Vancouver, ISO, and other styles
2

Mancini, Michael C. "Biomedical instrumentation and nanotechnology for image-guided cancer surgery." Diss., Georgia Institute of Technology, 2011. http://hdl.handle.net/1853/43657.

Full text
Abstract:
Once diagnosed, cancer is treated by surgical resection, chemotherapy, radiation therapy, or a combination of these therapies. It is intuitive that physically and completely removing a solid tumor would be an effective treatment. A complete resection of the tumor mass, defined by surgical margins that are clear of neoplasia, is prognostic for a decreased chance of cancer recurrence and an increased survival rate. In practice, complete resection is difficult. A surgeon primarily has only their senses of touch and sight to provide "real-time" guidance in the removal of a tumor while in the operating room. Preoperative imaging can guide a surgeon to a tumor but does not give a continuous update of surgical progress. Intraoperative pathology is limited to a few slides worth of samples: a product of its time-consuming nature and the limited time a patient can remain under general anesthesia. Technologies to guide a surgeon in effecting complete resection of a tumor mass during the surgical procedure would greatly increase cancer survival rates by lowering rates of cancer recurrence; such a technology would also reduce the need for follow-up chemotherapy or radiation therapy. Here, we describe a prototype instrumentation system that can provide intraoperative guidance with exogenous optical contrast agents. The instrumentation combines interactive point excitation, local spectroscopy, and widefield fluorescence imaging to enable low-cost surgical guidance using FDA-approved fluorescent dyes, semiconductor quantum dots (QDs), or surface-enhanced Raman scattering (SERS) nanoparticles. The utility of this surgical system is demonstrated in rodent tumor models using an FDA-approved fluorescent dye, indocyanine green (ICG), and is then more extensively demonstrated with a pre-clinical study of spontaneous tumors in companion canines. The pre-clinical studies show a high sensitivity in detecting a variety of canine tumors with a low false positive rate, as verified by pathology. We also present a fundamental study on the behavior of quantum dots. QDs are a promising fluorophore for biological applications, including as a surgical contrast agent. To use QDs for in vivo human imaging, toxicity concerns must be addressed first. Although it is suspected that QDs may be toxic to an organism based on the heavy-metal elemental composition of QDs, overt organism toxicity is not seen in long-term animal model studies. We have found that some reactive oxygen species (ROS) generated by the host inflammatory response can rapidly degrade QDs; in the case of hypochlorous acid, optical changes to the QDs are suggestive of degradation occurring within seconds. It is well-known that QDs are sequestered by the immune system when used in vivo---we therefore believe that QD degradation through an inflammatory response may represent a realizable in vivo mechanism for QD degradation. We demonstrate in an in vitro cell culture model that immune cells can degrade QDs through ROS exposure. Knowledge of the degradative processes that QDs would be subject to when used in vivo informs on adaptations that can be made to the QDs to resist degradation. Such adaptations will be important in developing QD-based contrast agents for image guided surgery.
APA, Harvard, Vancouver, ISO, and other styles
3

Fisher, Jessica Won Hee. "Effective Cancer Therapy Design Through the Integration of Nanotechnology." Thesis, Virginia Tech, 2008. http://hdl.handle.net/10919/34386.

Full text
Abstract:
Laser therapies can provide a minimally invasive treatment alternative to surgical resection of tumors. However, therapy effectiveness is limited due to nonspecific heating of target tissue, leading to healthy tissue injury and extended treatment durations. These therapies can be further compromised due to heat shock protein (HSP) induction in tumor regions where non-lethal temperature elevation occurs, thereby imparting enhanced tumor cell viability and resistance to subsequent therapy treatments. Introducing nanoparticles (NPs), such as multi-walled nanotubes (MWNTs) or carbon nanohorns (CNHs), into target tissue prior to laser irradiation increases heating selectivity permitting more precise thermal energy delivery to the tumor region and enhances thermal deposition thereby increasing tumor injury and reducing HSP expression induction. This research investigates the impact of MWNTs and CNHs in untreated and laser-irradiated monolayer cell culture, tissue phantoms, and/or tumor tissue from both thermal and biological standpoints. Cell viability remained high for all unheated NP-containing samples, demonstrating the non-toxic nature of both the nanoparticle and the alginate phantom. Up-regulation of HSP27, 70 and 90 was witnessed in samples that achieved sub-lethal temperature elevations. Tuning of laser parameters permitted dramatic temperature elevations, decreased cell viability, and limited HSP induction in NP-containing samples compared to those lacking NPs. Preliminary work showed MWNT internalization by cells, which presents imaging and multi-modal therapy options for NT use. The lethal combination of NPs and laser light and NP internalization reveals these particles as being viable options for enhancing the thermal deposition and specificity of hyperthermia treatments to eliminate cancer.
Master of Science
APA, Harvard, Vancouver, ISO, and other styles
4

Kim, Gloria J. "Cancer nanotechnology engineering multifunctional nanostructures for targeting tumor cells and vasculatures /." Diss., Atlanta, Ga. : Georgia Institute of Technology, 2007. http://hdl.handle.net/1853/22610.

Full text
Abstract:
Thesis (Ph. D.)--Biomedical Engineering, Georgia Institute of Technology, 2007.
Committee Chair: Nie, Shuming; Committee Member: Lyon, L. Andrew; Committee Member: McIntire, Larry V.; Committee Member: Murthy, Niren; Committee Member: Prausnitz, Mark R.
APA, Harvard, Vancouver, ISO, and other styles
5

Sathe, Tushar R. "Integrated Magnetic and Optical Nanotechnology for Early Cancer Detection and Monitoring." Diss., Georgia Institute of Technology, 2007. http://hdl.handle.net/1853/19868.

Full text
Abstract:
Despite significant developments in imaging modalities and therapeutics, cancer mortality rates remain unchanged. Detecting cancer before it has spread to other organs improves patient outcome dramatically. Therefore, greater emphasis must be placed on developing novel technology for early cancer detection and disease monitoring. Nanometer-sized materials have unique optoelectronic and magnetic properties. In particular, semiconductor quantum dots (QD) are a new class of fluorophores that are bright, photostable, and can be simultaneously excited to emit different wavelengths of light. Magnetic iron oxide nanoparticles are another class of unique nanomaterials that exhibit superparamagnetism and are strongly magnetized only in the presence of a magnetic field. In this dissertation, we describe the integration of semiconductor QDs and magnetic iron oxide nanoparticles and potential applications for (i) early detection of cancer biomarkers through routine screening, and (ii) disease monitoring through the capture and analysis of rare circulating tumor cells. First, we describe the development of integrated magneto-optical beads that can be optically encoded and magnetically separable for isolating low amounts of biomolecules from solution. Second, we demonstrate improved detection sensitivity by combining immunomagnetic beads and highly luminescent nanoparticles in a sandwich assay. Next, we describe integration of magnetic and QD nanotechnology for the selective capture and molecular profiling of rare cells. We demonstrate the ability to spectroscopically determine relative molecular levels of markers to identify invasive cells. As disease monitoring requires the analysis of patient blood samples, we have also studied nanoparticle-cell interactions using QDs to determine nanoparticle behavior in whole blood as a function of surface coatings. We observed that anionic nanoparticles with carboxylic acid groups (-COOH) were strongly associated with leukocytes, but interestingly this association was cell specific. Hydroxyl-modified QDs (QD-OH) suppressed binding and uptake by leukocytes as efficiently as PEG-modified QDs. The integration of nanotechnologies represents a new and exciting approach that has the potential to push the limits of detection sensitivity and permit isolation and profiling of multiple biomarkers from large sample volumes.
APA, Harvard, Vancouver, ISO, and other styles
6

Drah, Mustafa. "The development of nanotechnology-based detection systems for the diagnosis of breast cancer." University of the Western Cape, 2015. http://hdl.handle.net/11394/5021.

Full text
Abstract:
Philosophiae Doctor - PhD
Breast cancer is one of the major causes of death in South Africa. About 1 in 29 South African women are at risk of developing this type of cancer in their lifetime. The global incidence of breast cancer also increases annually with over 1 million new cases diagnosed every year. Molecular diagnostic techniques such as qRT-PCR, Fluorescent In Situ Hybridization (FISH), Immunohistochemistry (IHC) and ELISA are used to diagnose breast cancer. Some of these diagnostic techniques make use organic fluorophores as fluorescent reporter molecules. The principle of all these diagnostic techniques is reliant on the detection of molecular biomarkers that are associated with the disease. In most cases these molecular biomarkers are DNA, RNA or proteins that are up-regulated in response to or as a result of the disease. The first aim of this study was therefore to identify membrane proteins that are up-regulated in cancers that can potentially be used as biomarkers for the detection of breast cancer. The second aim of this study was to investigate the application of quantum dots in the development of a molecular diagnostic test that can detect a breast cancer biomarker. The most commonly used method to identify molecular biomarkers for diseases have traditionally been gene expression analysis using technologies such as DNA microarray. These technologies have certain limitations and have therefore not been very successful in identifying useful disease biomarkers. Biomarker II discovery by proteomics can overcome some of these limitations and is potentially a more suitable method to identify molecular biomarkers for breast cancer. In this study proteomics in combination with Stable Isotope Labelling with Amino Acids in Cell Culture SILAC was used to do a comparative analysis of the expression levels of membrane proteins present in a human breast cancer cell line (MCF-7) derived from a breast cancer patient and a human breast cell line (MCF- 12A) derived from a healthy individual. This led to the identification of the transmembrane protein, GFRA1 as potential new biomarker for breast cancer. This study showed that this protein is over expressed in MCF-7 cells as compared to MCF-12A cells and that it is also highly expressed in the myoepthelial cells of the milk ducts of breast cancer patients. This study also demonstrates the use of molecular beacon technology to develop a DNA probe for the detection of cDNA encoding the CK19 gene, which is a known biomarker for breast cancer. In the development of this probe, quantum dots were used as the fluorescence reporter. This molecular beacon probe was able to demonstrate the over expression of CK19 in MCF-7 cells. This study shows that this technology can potentially be used as a diagnostic test for breast cancer and since quantum dots are used in the development of these molecular beacon probes, this diagnostic test can potentially facilitate the development of multiplex detection systems for the diagnosis of breast cancer. Molecular beacon technology can potentially also be used to detect novel biomarkers such as GFRA1.
APA, Harvard, Vancouver, ISO, and other styles
7

Motala, Ismail Mohammed, and Saartjie Roux. "Formulation of an optimal non-targeted liposome preparation for fusion with tumour cell line membranes." Thesis, Nelson Mandela Metropolitan University, 2016. http://hdl.handle.net/10948/12220.

Full text
Abstract:
The most common treatment used for cancer is chemotherapy. Chemotherapeutic agents have a greater affinity for rapidly dividing cells which is a characteristic of tumour cells. Although anti-cancer agents have their advantages in providing anti-cancer effects, they can be seen as highly toxic molecules posing a threat to normal healthy tissue within the human body. However, these toxic therapies need to be delivered to tumour sites without damaging healthy tissue. Liposomes can serve as a delivery system for these toxic molecules and be delivered to the tumour site via the EPR effect. Hence, liposomes that fuse with tumour cell line membranes are advantageous in delivering payloads of drugs directly into the tumour cell without damaging normal healthy tissue. The aim of the study was to formulate an optimised liposome preparation in order to enhance cellular uptake by MCF-7, Caco-2 and C3A cancer cell lines via membrane fusion. The optimal liposome formulation was aimed to be prepared utilising a statistical design approach in order to determine the ranges of the parameters that were furthermost optimal in formulating an ideal liposome preparation. The primary screening design was conducted using a 24-1 fractional factorial design that took into account the four parameters that were used to determine the optimisation of the liposomal preparation. The four variables used in the liposome preparation were the phospholipid type (PS or DOPE), the concentration of cholesteryl hemisuccinate (CHEMS) (10 – 40 %), the concentration of PEG2000-PE (0.5 – 4 %) and liposome size (100 or 200 nm). Liposomes were prepared using thin film hydration method and characterisation for size and zeta potential was carried out using photon correlation spectroscopy (PCS). Visual characterisation of liposome size was carried out using atomic force microscopy (AFM). Liposomes were exposed the cancer cell lines with visualisation and uptake being measured using fluorescent microscopy and flow cytometry, respectively. An optimal liposome preparation was prepared following the statistical design method. The optimal liposome preparation consisted of phospholipid type PS, 22.91 % of CHEMS, 4 % of PEG2000-PE and a liposome size of 200 nm. AFM analysis has shown that optimal liposome sizes ranged between 130 and 170 nm. Flow cytometry analysis indicated high level of liposome uptake with actual values falling below the predicted values set out by the statistical design. Fluorescence microscopy captured images of the fluorescent liposomes concentrated on the membrane of cells. The objective of the study was to determine from literature which variables would be desirable in preparing an optimal non-targeted liposome preparation. This was achieved by identifying four such variables and utilising them in a statistical design approach which was screened in order to determine the ideal parameters in preparing the optimised liposome batch. Therefore, from the results obtained it can be concluded that the aim of the study were met by preparing an optimal liposome preparation that has the ability to fuse with the tumour cell line membranes.
APA, Harvard, Vancouver, ISO, and other styles
8

Platt, Virginia M. "Surface functionalization of liposomes with proteins and carbohydrates for use in anti-cancer applications." Diss., Search in ProQuest Dissertations & Theses. UC Only, 2010. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:3390073.

Full text
Abstract:
Thesis (Ph.D.)--University of California, San Francisco with the University of California, Berkeley, 2010.
Source: Dissertation Abstracts International, Volume: 71-02, Section: B, page: . Adviser: Francis C. Szoka.
APA, Harvard, Vancouver, ISO, and other styles
9

Petryk, Alicia Ailie. "Magnetic nanoparticle hyperthermia as an adjuvant cancer therapy with chemotherapy." Thesis, Dartmouth College, 2014. http://pqdtopen.proquest.com/#viewpdf?dispub=3634608.

Full text
Abstract:

Magnetic nanoparticle hyperthermia (mNPH) is an emerging cancer therapy which has shown to be most effective when applied in the adjuvant setting with chemotherapy, radiation or surgery. Although mNPH employs heat as a primary therapeutic modality, conventional heat may not be the only cytotoxic effect. As such, my studies have focused on the mechanism and use of mNPH alone and in conjunction with cisplatinum chemotherapy in murine breast cancer cells and a related in vivo model. MNPH was compared to conventional microwave tumor heating, with results suggesting that mNPH (mNP directly injected into the tumor and immediately activated) and 915 MHz microwave hyperthermia, at the same thermal dose, result in similar tumor regrowth delay kinetics. However, mNPH shows significantly less peri-tumor normal tissue damage. MNPH combined with cisplatinum also demonstrated significant improvements in regrowth delay over either modality applied as a monotherapy. Additional studies demonstrated that a relatively short tumor incubation time prior to AMF exposure (less than 10 minutes) as compared to a 4-hour incubation time, resulted in faster heating rates, but similar regrowth delays when treated to the same thermal dose. The reduction of heating rate correlated well with the observed reduction in mNP concentration in the tumor observed with 4 hour incubation. The ability to effectively deliver cytotoxic mNPs to metastatic tumors is the hope and goal of systemic mNP therapy. However, delivering relevant levels of mNP is proving to be a formidable challenge. To address this issue, I assessed the ability of cisplatinum to simultaneously treat a tumor and improve the uptake of systemically delivered mNPs. Following a cisplatinum pretreatment, systemic mNPs uptake was increased by 3.1 X, in implanted murine breast tumors. Additional in vitro studies showed the necessity of a specific mNP/ Fe architecture and spatial relation for heat-based cytotoxicity in cultured cells.

APA, Harvard, Vancouver, ISO, and other styles
10

Ahmed, Muneer. "The application of magnetic nanotechnology to the surgical management of non-palpable breast cancer." Thesis, King's College London (University of London), 2015. http://kclpure.kcl.ac.uk/portal/en/theses/the-application-of-magnetic-nanotechnology-to-the-surgical-management-of-nonpalpable-breast-cancer(e18d9196-1462-4302-b95e-aa7f64afc1c7).html.

Full text
Abstract:
Background: Breast cancer is the most common cancer in the United Kingdom, with over one-third of all cases diagnosed annually being clinically occult (non-palpable). The current standard of care is surgical wide local excision using wire-guided localization and axillary staging by sentinel node biopsy. Wire-guided localization possesses limitations, which have resulted in alternative localization techniques being developed – although these have failed to gain mainstream acceptance. This thesis examined the current evidence supporting other localization techniques and aimed to develop an alternative, overcoming existing limitations. Materials and methods: This thesis examined a handheld magnetometer and magnetic tracer for localization properties within pre-clinical phantom models, progressing to the development of an in vivo porcine model, which was also used to assess concurrent sentinel lymph node biopsy. This was followed by the establishment of the first, in-man feasibility study of a magnetic tracer for sentinel node and occult lesion localization using an intra-tumoral injection of magnetic tracer for patients with non-palpable breast cancer (MagSNOLL trial, UKCRN 14979). Results: This thesis demonstrated the ability of a magnetic tracer to localise at a specific site within phantom models. This was replicated within an in vivo porcine model in addition to concurrent sentinel lymph node biopsy with a single injection of the magnetic tracer. These findings were translated into a clinical trial (MagSNOLL), which demonstrated that an intra-tumoral injection of magnetic tracer allowed successful lesion localization independently of a wire. Concurrent magnetic sentinel lymph node biopsy was demonstrated to be feasible but inferior to the standard ‘dual technique’ of radioisotope and blue dye. Conclusion: Magnetic lesion localization is feasible without the need for a wire or radioisotopes. Further work to assess the retention of the magnetic tracer in vivo and optimisation of sentinel node identification rates are required.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cancer nanotechnology"

1

Grobmyer, Stephen R., and Brij M. Moudgil, eds. Cancer Nanotechnology. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-609-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zeineldin, Reema, ed. Cancer Nanotechnology. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6646-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cancer nanotechnology: Methods and protocols. New York: Humana Press, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Nanomedicine and cancer. Boca Raton, FL: CRC Press/Taylor & Francis Group, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cancer nanotechnology: Principles and applications in radiation oncology. Boca Raton: Taylor & Francis, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Institute of Medicine (U.S.). Planning Committee on Policy Issues in Nanotechnology and Oncology and National Cancer Policy Forum (U.S.), eds. Nanotechnology and oncology: Workshop summary. Washington,D.C: National Academies Press, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cucuzza, Michele. Il male curabile: La sfida di Mauro Ferrari, il matematico italiano che sta rivoluzionando la lotta ai tumori. [Milan, Italy]: Rizzoli, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mirkin, Chad A., Thomas J. Meade, Sarah Hurst Petrosko, and Alexander H. Stegh, eds. Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-16555-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Tiwari, Ashutosh, Hirak K. Patra, and Jeong-Woo Choi. Advanced theranostics materials. Hoboken, New Jersey: John Wiley & Sons Inc.-Scrivener, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kaul, Sunil C. Mortalin Biology: Life, Stress and Death. Dordrecht: Springer Netherlands, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cancer nanotechnology"

1

Grobmyer, Stephen R., and Nobutaka Iwakuma. "Nanotechnology." In Encyclopedia of Cancer, 2451–54. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_3967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Grobmyer, Stephen R., and Nobutaka Iwakuma. "Nanotechnology." In Encyclopedia of Cancer, 1–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_3967-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Grobmyer, Stephen R., and Nobutaka Iwakuma. "Nanotechnology." In Encyclopedia of Cancer, 3013–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_3967.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Watts, Kara L., and Joshua M. Stern. "Nanotechnology." In Management of Urologic Cancer, 213–31. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781118868126.ch15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Janát-Amsbury, Margit M., and You Han Bae. "Nanotechnology in Cancer." In Cancer Drug Discovery and Development, 703–30. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9135-4_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Peroulis, Dimitrios, Prashant R. Waghmare, Sushanta K. Mitra, Supone Manakasettharn, J. Ashley Taylor, Tom N. Krupenkin, Wenguang Zhu, et al. "Cancer Modeling." In Encyclopedia of Nanotechnology, 363. Dordrecht: Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-90-481-9751-4_100096.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Alshamsan, Aws. "Nanotechnology-Based Cancer Vaccine." In Methods in Molecular Biology, 257–70. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6646-2_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zahr, Alisar S., and Michael V. Pishko. "Nanotechnology for Cancer Chemotherapy." In Nanotechnology in Drug Delivery, 491–518. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-0-387-77668-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Grobmyer, Stephen R., Nobutaka Iwakuma, Parvesh Sharma, and Brij M. Moudgil. "What Is Cancer Nanotechnology?" In Methods in Molecular Biology, 1–9. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-609-2_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kommu, Sashi S., Lidong Qin, Louis Brousseau, Amrith Raj Rao, Philippe Grange, Mauro Ferrari, Mauro Ferrari, et al. "Nanotechnology and Prostate Cancer." In Prostate Cancer: A Comprehensive Perspective, 555–74. London: Springer London, 2012. http://dx.doi.org/10.1007/978-1-4471-2864-9_45.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cancer nanotechnology"

1

Mojarrad, Mehran. "Nanotechnology Based Cancer Therapies." In ASME 2007 2nd Frontiers in Biomedical Devices Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/biomed2007-38034.

Full text
Abstract:
By all accounts cancer remains the leading cause of death for humans of age less than 85 years old. This is partly because of the fact that there has been success in addressing other competing diseases such as cardiovascular leading to an overall drop in the rate of such disease where as after four decades of research success in cancer therapy remains limited. This places a greater demand on developing new therapies to treat cancer. With recent advances in nanotechnology field as applied in medicine there are new opportunities to detect, more effectively target and treat cancer and monitor the therapy while minimizing the damage to normal tissues and cells.
APA, Harvard, Vancouver, ISO, and other styles
2

Mironidou-Tzouveleki, Maria, Konstantinos Imprialos, and Athanasios Kintsakis. "Nanotechnology in cancer treatment." In SPIE NanoScience + Engineering, edited by Hooman Mohseni, Massoud H. Agahi, and Manijeh Razeghi. SPIE, 2011. http://dx.doi.org/10.1117/12.898643.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Thomas, D. G., R. V. Pappu, and N. A. Baker. "Ontologies for cancer nanotechnology research." In 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2009. http://dx.doi.org/10.1109/iembs.2009.5333941.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Phan, John H., Andrew N. Young, and May D. Wang. "Selecting Clinically-Driven Biomarkers for Cancer Nanotechnology." In Conference Proceedings. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2006. http://dx.doi.org/10.1109/iembs.2006.4398157.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Phan, John H., Andrew N. Young, and May D. Wang. "Selecting Clinically-Driven Biomarkers for Cancer Nanotechnology." In Conference Proceedings. Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE, 2006. http://dx.doi.org/10.1109/iembs.2006.259746.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Shashidharan, Sreenesh, and Jincy Johny. "Nanotechnology based terahertz imaging for cancer diaganosis." In 2015 International Conference on Electrical, Electronics, Signals, Communication and Optimization (EESCO). IEEE, 2015. http://dx.doi.org/10.1109/eesco.2015.7253715.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Suraj. H, A. V., Bhavyabhushan yadav, R. Vinaya Ajjampura., and K. Sunil. "QCA and nanotechnology based cancer inhibition system." In 2010 3rd International Conference on Advanced Computer Theory and Engineering (ICACTE 2010). IEEE, 2010. http://dx.doi.org/10.1109/icacte.2010.5579255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ferrari, Mauro. "Nanotechnology and individualized oncology." In AACR International Conference: Molecular Diagnostics in Cancer Therapeutic Development– Sep 27-30, 2010; Denver, CO. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/diag-10-ed1a-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Stokol, Tracy, Mandy B. Esch, Nozomi Nishimura, Chris Schaffer, Janelle L. Daddona, David J. Post, and Dhruv P. Desai. "Little Channels, Big Disease: Using Microfluidics to Investigate Cancer Metastasis." In ASME 2011 9th International Conference on Nanochannels, Microchannels, and Minichannels. ASMEDC, 2011. http://dx.doi.org/10.1115/icnmm2011-58298.

Full text
Abstract:
The leading cause of death in human patients with malignant cancer is the dissemination of the primary tumor to secondary sites throughout the body. It is well known that cancers metastasize to certain tissues (e.g. breast cancer typically spreads to the lungs. brain and bone), in a pattern that cannot be explained by blood flow from the primary tumor or simple mechanical arrest. Circulating tumor cells usually arrest in the microvasculature of target tissues. At these sites, they must adhere to the endothelium, survive, proliferate and extravasate in order to form a secondary tumor. In vitro tools that appropriately mimic the microvasculature in which cancer metastasis occurs have been largely unavailable. With the advent of microfluidic and nanotechnology, we can now more accurately model the complexity of the microvascular environment, in terms of representative endothelial cells, geometry, shear stress and exposure to organ-specific environmental cues. This talk will focus on the use of microfluidic devices to explore mechanisms involved in tumor-endothelial cell interactions that govern cancer metastasis to organ specific sites.
APA, Harvard, Vancouver, ISO, and other styles
10

Lam, Kit S., and Ruiwu Liu. "From Combinatorial Chemistry to Nanotechnology to Cancer Therapy." In The Twenty-Third American and the Sixth International Peptide Symposium. Prompt Scientific Publishing, 2013. http://dx.doi.org/10.17952/23aps.2013.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cancer nanotechnology"

1

Drezek, Rebekah. Nanotechnology-Enabled Optical Molecular Imaging of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2010. http://dx.doi.org/10.21236/ada542313.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Drezek, Rebekah. Nanotechnology-Enabled Optical Molecular Imaging of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada586328.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Drezek, Rebekah. Nanotechnology-Enabled Optical Molecular Imaging of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 2013. http://dx.doi.org/10.21236/ada598494.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Drezek, Rebekah. Nanotechnology-Enabled Optical Molecular Imaging of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, July 2011. http://dx.doi.org/10.21236/ada550240.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Herman, James. Advanced Lung Cancer Screening: An Individualized Molecular Nanotechnology Approach. Fort Belvoir, VA: Defense Technical Information Center, August 2013. http://dx.doi.org/10.21236/ada589726.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Herman, James. Advanced Lung Cancer Screening: An Individualized Molecular Nanotechnology Approach. Fort Belvoir, VA: Defense Technical Information Center, August 2014. http://dx.doi.org/10.21236/ada618652.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hatefi, Arash. Development of a Nanotechnology Platform for Prostate Cancer Gene Therapy. Fort Belvoir, VA: Defense Technical Information Center, July 2012. http://dx.doi.org/10.21236/ada581408.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hatefi, Arash. Development of a Nanotechnology Platform for Prostate Cancer Gene Therapy. Fort Belvoir, VA: Defense Technical Information Center, July 2011. http://dx.doi.org/10.21236/ada554393.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Feltmate, Colleen. Application of Nanotechnology in the Targeted Release of Anticancer Drugs in Ovarian Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, December 2007. http://dx.doi.org/10.21236/ada486569.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Feltmate, Colleen. Application of Nanotechnology in the Targeted Release of Anticancer Drugs in Ovarian Cancer Treatment. Fort Belvoir, VA: Defense Technical Information Center, December 2006. http://dx.doi.org/10.21236/ada481424.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cancer nanotechnology' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography